DUBLIN, Feb. 19, 2020 /PRNewswire/ -- The "Primary Ciliary Dyskinesia (PCD) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Primary Ciliary Dyskinesia (PCD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Ciliary Dyskinesia (PCD) market.
A detailed picture of the Primary Ciliary Dyskinesia (PCD) pipeline landscape is provided, which includes the disease overview and Primary Ciliary Dyskinesia (PCD) treatment guidelines. The assessment part of the report embraces in-depth Primary Ciliary Dyskinesia (PCD) commercial assessment and clinical assessment of the Primary Ciliary Dyskinesia (PCD) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Ciliary Dyskinesia (PCD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Primary Ciliary Dyskinesia (PCD) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Primary Ciliary Dyskinesia (PCD) treatment.
- Primary Ciliary Dyskinesia (PCD) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Primary Ciliary Dyskinesia (PCD) market.
Scope of the Report
- The Primary Ciliary Dyskinesia (PCD) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Primary Ciliary Dyskinesia (PCD) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Primary Ciliary Dyskinesia (PCD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
- Detailed Primary Ciliary Dyskinesia (PCD) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Primary Ciliary Dyskinesia (PCD).
Key Topics Covered
1. Report Introduction
2. Primary Ciliary Dyskinesia (PCD)
2.1. Overview
2.2. History
2.3. Primary Ciliary Dyskinesia (PCD) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Primary Ciliary Dyskinesia (PCD) Diagnosis
2.6.1. Diagnostic Guidelines
3. Primary Ciliary Dyskinesia (PCD) Current Treatment Patterns
3.1. Primary Ciliary Dyskinesia (PCD) Treatment Guidelines
4. Primary Ciliary Dyskinesia (PCD) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Primary Ciliary Dyskinesia (PCD) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Primary Ciliary Dyskinesia (PCD) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Primary Ciliary Dyskinesia (PCD) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Primary Ciliary Dyskinesia (PCD) Late Stage Products (Phase-III)
7. Primary Ciliary Dyskinesia (PCD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Ciliary Dyskinesia (PCD) Discontinued Products
13. Primary Ciliary Dyskinesia (PCD) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Primary Ciliary Dyskinesia (PCD) Key Companies
15. Primary Ciliary Dyskinesia (PCD) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being Dormant
16.2. Discontinued Products
16.2.1. Reasons for the Discontinuation
17. Primary Ciliary Dyskinesia (PCD) Unmet Needs
18. Primary Ciliary Dyskinesia (PCD) Future Perspectives
19. Primary Ciliary Dyskinesia (PCD) Analyst Review
Companies Mentioned
- Santhera Pharmaceuticals
- Vertex Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v38uii
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/2020-global-primary-ciliary-dyskinesia-pcd-pipeline-landscape-overview-301007422.html
SOURCE Research and Markets
